眾生藥業(002317.SZ):控股子公司獲得一項韓國專利證書
格隆匯10月20日丨眾生藥業(002317.SZ)公佈,近日,公司控股子公司廣東眾生睿創生物科技有限公司(“眾生睿創”)收到韓國知識產權局頒發的專利證書,專利名稱為항인플루엔자 바이러스 피리미딘 유도체 (抗流感病毒嘧啶衍生物)。
該專利是公司控股子公司眾生睿創用於預防和治療甲型流感及人禽流感的一類創新藥物ZSP1273項目的化合物專利,屬於該項目的核心專利。ZSP1273是國內首個獲批臨牀試驗的治療甲型流感的小分子RNA 聚合酶抑制劑,目前正在開展治療成人單純性甲型流感的III期臨牀試驗,以進一步確證其療效和安全性。ZSP1273顆粒劑已獲得國家藥品監督管理局的臨牀試驗批准通知書,正積極準備開展用於兒童的單純性流感II期臨牀研究。
此次ZSP1273項目化合物專利獲得韓國知識產權局的授權,是該項目化合物專利繼獲得中國、香港特別行政區、澳門特別行政區、俄羅斯、新加坡、新西蘭、澳大利亞、日本、南非等國家/地區專利授權後的又一個專利授權,該專利授權完善了ZSP1273項目的全球知識產權保護體系,是公司長期重視知識產權的體現。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.